These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 14558299)

  • 1. Nurses' observational study on the practice of secondary prevention in a cardiovascular department.
    Steffenino G; Galliasso M; Gastaldi C; Ricca N; Mangiacotti B
    Ital Heart J; 2003 Jul; 4(7):473-8. PubMed ID: 14558299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice.
    Faggiano P; Fattirolli F; Frisinghelli A; Piccioli L; Dasseni N; Silverii MV; Albricci L; D'Ambrosio G; Garrì R; Esposito L; Giallauria F
    Monaldi Arch Chest Dis; 2019 May; 89(2):. PubMed ID: 31107039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?
    George PB; Tobin KJ; Corpus RA; Devlin WH; O'Neill WW
    Am Heart J; 2001 Nov; 142(5):857-63. PubMed ID: 11685175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherosclerotic disease and risk factor modification in Saudi Arabia: a call to action.
    Al-Omran M
    Vasc Health Risk Manag; 2012; 8():349-55. PubMed ID: 22701328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
    Griffiths B; Lesosky M; Ntsekhe M
    S Afr Med J; 2014 Jun; 104(7):483-7. PubMed ID: 25214049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study.
    Gyberg V; Kotseva K; Dallongeville J; Backer GD; Mellbin L; Rydén L; Wood D; Bacquer DD;
    Eur J Prev Cardiol; 2015 Jun; 22(6):753-61. PubMed ID: 24691153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.
    Kotseva K; De Backer G; De Bacquer D; Rydén L; Hoes A; Grobbee D; Maggioni A; Marques-Vidal P; Jennings C; Abreu A; Aguiar C; Badariene J; Bruthans J; Castro Conde A; Cifkova R; Crowley J; Davletov K; Deckers J; De Smedt D; De Sutter J; Dilic M; Dolzhenko M; Dzerve V; Erglis A; Fras Z; Gaita D; Gotcheva N; Heuschmann P; Hasan-Ali H; Jankowski P; Lalic N; Lehto S; Lovic D; Mancas S; Mellbin L; Milicic D; Mirrakhimov E; Oganov R; Pogosova N; Reiner Z; Stöerk S; Tokgözoğlu L; Tsioufis C; Vulic D; Wood D;
    Eur J Prev Cardiol; 2019 May; 26(8):824-835. PubMed ID: 30739508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease.
    Hussain MA; Al-Omran M; Mamdani M; Eisenberg N; Premji A; Saldanha L; Wang X; Verma S; Lindsay TF
    JAMA Surg; 2016 Aug; 151(8):742-50. PubMed ID: 27050566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
    Boytsov S; Logunova N; Khomitskaya Y;
    Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Peterson GG; Pu J; Magid DJ; Barterian L; Kranker K; Barna M; Conwell L; Rose A; Blue L; Markovitz A; McCall N; Markovich P
    JAMA Cardiol; 2021 Sep; 6(9):1050-1059. PubMed ID: 34076665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication adherence, biological and lifestyle risk factors in patients with myocardial infarction: a ten-year follow-up on socially differentiated cardiac rehabilitation.
    Hald K; Larsen FB; Nielsen KM; Meillier LK; Johansen MB; Larsen ML; Christensen B; Nielsen CV
    Scand J Prim Health Care; 2019 Jun; 37(2):182-190. PubMed ID: 31122102
    [No Abstract]   [Full Text] [Related]  

  • 15. Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry.
    Urbinati S; Olivari Z; Gonzini L; Savonitto S; Farina R; Del Pinto M; Valbusa A; Fantini G; Mazzoni A; Maggioni AP;
    Eur J Prev Cardiol; 2015 Dec; 22(12):1548-56. PubMed ID: 25452625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of cardiovascular secondary prevention guidelines in clinical practice: a nationwide survey in Italy.
    Perrone-Filardi P; Poli A; Ambrosio G; Proto C; Chimini C; Chiariello M
    Nutr Metab Cardiovasc Dis; 2012 Feb; 22(2):149-53. PubMed ID: 20875948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Missed opportunities for the secondary prevention of cardiovascular disease in Canada.
    Hackam DG; Leiter LA; Yan AT; Yan RT; Mendelsohn A; Tan M; Zavodni L; Chen R; Tsang JL; Kundi A; Lin PJ; Fitchett DH; Langer A; Goodman SG;
    Can J Cardiol; 2007 Dec; 23(14):1124-30. PubMed ID: 18060097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project.
    Xing Y; Liu J; Hao Y; Liu J; Huo Y; Smith SC; Ge J; Ma C; Han Y; Fonarow GC; Taubert KA; Morgan L; Yang N; Zhou M; Zhao D;
    Am Heart J; 2019 Jun; 212():120-128. PubMed ID: 30986750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.